Search Results for "Heart Failure"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Heart Failure. Results 221 to 230 of 277 total matches.
Influenza Vaccines for 2025-2026
The Medical Letter on Drugs and Therapeutics • Sep 29, 2025 (Issue 1738)
disease
(recent MI or hospitalization for heart failure), use of a
high-dose inactivated vaccine ...
Annual vaccination against influenza A and B viruses
is recommended in the US for everyone ≥6 months
old without a contraindication. Influenza vaccines
available in the US for the 2025-2026 season are listed
in Table 2.
Med Lett Drugs Ther. 2025 Sep 29;67(1738):153-8 doi:10.58347/tml.2025.1738a | Show Introduction Hide Introduction
Drugs That Cause Sexual Dysfunction: An Update
The Medical Letter on Drugs and Therapeutics • Aug 07, 1992 (Issue 876)
, such as guanadrel (Hylorel), can cause impotence and ejaculatory failure. Centrally acting sympatholytics ...
Many commonly used drugs can interfere with sexual function in both men and women, causing loss of libido, interfering with erection or ejaculation in men, and delaying or preventing orgasm in women. Drug-related effects on sexual function may be difficult to distinguish from the effects of depression or disease, but most are reversible when drug use is stopped and sometimes when dosage is decreased. Since many patients are reluctant to talk about sexual difficulties, physicians may wish to ask about the possibility of drug-induced sexual dysfunction, particularly when they have...
Pravastatin And Simvastatin for Hypercholesterolemia
The Medical Letter on Drugs and Therapeutics • Mar 08, 1991 (Issue 839)
mg/d and 16% with 40 mg/d (JF Walker and JA Tobert, Eur Heart J, 8 suppl E:93,
1987). Similar ...
Pravastatin (Pravachol - Bristol-Myers Squibb) and simvastatin (Zocor - Merck), two new inhibitors of cholesterol synthesis similar to lovastatin (Mevacor - Merck), have been marketed in Canada and several European countries and may soon be available in the USA for treatment of high plasma cholesterol concentrations. Drugs already marketed here for this indication were recently reviewed in The Medical Letter (Volume 33, page 1, January 11, 1991).
Antibacterial Prophylaxis for Dental, GI and GU Procedures
The Medical Letter on Drugs and Therapeutics • Jul 18, 2005 (Issue 1213)
are based on
those recommended by the American Heart
Association for prevention of endocarditis.
2 ...
Many physicians believe that antimicrobial prophylaxis before procedures that may cause transient bacteremia can prevent endocarditis and prosthetic joint infection in patients at increased risk for these disorders. The effectiveness of this common practice has never been established by controlled trials in humans.
Clarithromycin in Patients with Coronary Artery Disease
The Medical Letter on Drugs and Therapeutics • May 21, 2018 (Issue 1547)
result in treatment failure in patients with pneumococcal infection.
13. Other possible pathogens ...
The FDA has warned that use of the macrolide
antibiotic clarithromycin (Biaxin, and generics) may
increase the risk of cardiovascular morbidity and
mortality in patients with heart disease.
Table: GLP-1 and GIP/GLP-1 Receptor Agonists for Chronic Weight Management (online only)
The Medical Letter on Drugs and Therapeutics • Aug 05, 2024 (Issue 1708)
reactions
▶ Increased heart rate
▶ Renal impairment and acute renal failure
▶ Possible pancreatitis ...
View the Table: GLP-1 and GIP/GLP-1 Receptor Agonists for Chronic Weight Management
Med Lett Drugs Ther. 2024 Aug 5;66(1708):e1-2 doi:10.58347/tml.2024.1708d | Show Introduction Hide Introduction
Drugs for Migraine
The Medical Letter on Drugs and Therapeutics • Jun 12, 2023 (Issue 1678)
, and orthostatic
hypotension. They should not be used in patients
with decompensated heart failure.
ANTISEIZURE ...
An oral nonopioid analgesic is often sufficient for
acute treatment of mild to moderate migraine pain
without severe nausea or vomiting. A triptan is the
drug of choice for treatment of moderate to severe
migraine in most patients without vascular disease.
Treatment of pain when it is still mild to moderate in
intensity improves headache response and reduces
the risk of recurrence.
Med Lett Drugs Ther. 2023 Jun 12;65(1678):89-96 doi:10.58347/tml.2023.1678a | Show Introduction Hide Introduction
Testosterone Nasal Gel (Natesto) for Hypogonadism
The Medical Letter on Drugs and Therapeutics • May 11, 2015 (Issue 1468)
HYPOGONADISM — Failure of the testes to produce
adequate amounts of testosterone can lead to loss
of energy ...
The FDA has approved an intranasal gel formulation of
testosterone (Natesto – Trimel/Endo) for replacement
therapy in men with hypogonadism. Packaged in a
metered-dose pump, Natesto is the first intranasal
testosterone to become available in the US. Like other
testosterone products, it is classified as a schedule
III controlled substance. The FDA recently cautioned
against using testosterone to treat low testosterone
levels solely due to aging because the benefits and
safety of such use have not been established, and there
is a possible increased risk of myocardial infarction...
Safety of Aggressive Statin Therapy
The Medical Letter on Drugs and Therapeutics • Nov 22, 2004 (Issue 1196)
to ...
New guidelines from The National Cholesterol Education Program recommend, as a therapeutic option, lowering treatment goals for LDL cholesterol (LDL-C) from <100 mg/dL to <70 mg/dL for patients at very high risk for coronary heart disease and from 130 mg/dL to <100 mg/dL for those at moderately high risk. A likely consequence of these recommendations is increased use of statins and use of higher doses with a concomitant increase in adverse effects.
Lonapegsomatropin (Skytrofa) for Growth Hormone Deficiency
The Medical Letter on Drugs and Therapeutics • Feb 07, 2022 (Issue 1643)
following open heart or
abdominal surgery, multiple accidental trauma, or
acute respiratory failure ...
Lonapegsomatropin-tcgd (Skytrofa – Ascendis), a long-acting prodrug of recombinant human growth hormone (rhGH), has been approved by the FDA for
once-weekly subcutaneous (SC) treatment of growth
failure due to inadequate secretion of endogenous
growth hormone in children ≥1 year old who weigh
≥11.5 kg. It is the first once-weekly rhGH product to be
approved in the US; other available rhGH formulations
are administered more frequently.